Wall Street Analysts See Upside Potential for 5 Stocks with Rising Price Targets

01. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)

Upside Potential: 174%

On January 29, Oppenheimer analyst Jeff Jones reaffirmed his bullish outlook on Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a key player in the pharmaceutical industry, maintaining an “Outperform” rating on the stock. Additionally, Jones raised the price target for Corbus Pharmaceuticals from $20 to $51, suggesting a substantial upside potential of 174% relative to the closing market price on January 29. This reiteration of confidence by Jeff Jones underscores his positive assessment of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) position and growth prospects within the pharmaceutical sector. By maintaining an “Outperform” rating, Jones indicates his belief that Corbus Pharmaceuticals presents an attractive investment opportunity with favorable prospects for long-term growth and value appreciation. The increased price target of $51 reflects Jones’ optimistic view on Corbus Pharmaceuticals’ future performance and earnings potential. This adjustment signifies Jones’ conviction that Corbus Pharmaceuticals’ stock is currently undervalued relative to its anticipated earnings trajectory and growth opportunities. The revised price target is expected to enhance investor confidence in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) growth potential and contribute to positive sentiment surrounding the stock. Jones’ analysis and price target revision for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) are likely to influence investor perceptions and contribute to ongoing discussions about the company’s competitive positioning and growth trajectory within the pharmaceutical industry.

You can also take a look at 16 Most Undervalued Quality Stocks To Buy According To Hedge Funds and 12 Best Foreign Dividend Stocks To Invest In